XML 41 R21.htm IDEA: XBRL DOCUMENT
v3.20.4

Quarterly Information (Unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2020
Quarterly Information (Unaudited) |
Quarterly Information (Unaudited) | Note 15—Quarterly Information (Unaudited) The following table summarizes the unaudited statements of operations and comprehensive loss for each quarter of 2020 and 2019 (in thousands, except per share amounts):
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2020 | ​ | For the Quarter Ended
​ |  | ​ | March 31, |  | ​ | June 30, |  | ​ | September 30, |  | ​ | December 31,
Product sales, net (1) | ​ | $ | 23,537 | ​ | $ | 13,530 | ​ | $ | 26,114 | ​ | $ | 10,632
Total costs and expenses | ​ |  | 47,214 | ​ |  | 41,210 | ​ |  | 51,542 | ​ |  | 44,448
Loss from operations | ​ |  | (23,677) | ​ |  | (27,680) | ​ |  | (25,428) | ​ |  | (33,816)
Net loss | ​ |  | (29,031) | ​ |  | (33,294) | ​ |  | (38,463) | ​ |  | (37,273)
Basic and diluted net loss per share | ​ | $ | (0.53) | ​ | $ | (0.61) | ​ | $ | (0.66) | ​ | $ | (0.60)
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
2019 | ​ | For the Quarter Ended
​ |  | ​ | March 31, |  | ​ | June 30, |  | ​ | September 30, |  | ​ | December 31,
Product sales, net | ​ | $ | 21,779 | ​ | $ | 26,753 | ​ | $ | 29,856 | ​ | $ | 33,417
Total costs and expenses | ​ |  | 41,018 | ​ |  | 36,091 | ​ |  | 40,957 | ​ |  | 57,121
Loss from operations | ​ |  | (19,239) | ​ |  | (9,338) | ​ |  | (11,101) | ​ |  | (23,704)
Net loss | ​ |  | (24,345) | ​ |  | (14,453) | ​ |  | (16,463) | ​ |  | (29,225)
Basic and diluted net loss per share | ​ | $ | (0.50) | ​ | $ | (0.29) | ​ | $ | (0.33) | ​ | $ | (0.58)
| (1) | The COVID-19 pandemic led to a reduction in the number of elective cataract procedures from mid-March 2020 through late June 2020. In August 2020, the Centers for Medicare and Medicaid Services, the federal agency responsible for administering the Medicare program, confirmed the October 1, 2020 expiration of pass-through reimbursement for OMIDRIA under Medicare Part B, and consequently, our net revenues for September and the fourth quarter of 2020 were significantly reduced. In December 2020, CMS confirmed that OMIDRIA qualifies for separate payment when used on Medicare Part B patients in the ASC setting under CMS’ policy for non-opioid pain management surgical drugs, effective retroactive as of October 1, 2020.

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -URI http://asc.fasb.org/topic&trid=2126967 + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration